ME Therapeutics Holdings Inc. (CSE:METX)

Market Cap	59.80M -12.4%
Revenue (ttm)	n/a
Net Income	-1.38M
EPS	-0.05
Shares Out	30.05M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,300
Open	0.790
Previous Close	n/a
Day's Range	0.790 - 1.990
52-Week Range	0.790 - 9.500
Beta	0.06
Analysts	n/a
Price Target	n/a
Earnings Date	Jul 17, 2026

About ME Therapeutics Holdings

ME Therapeutics Holdings Inc., a preclinical stage biotechnology company, engages in the development of cancer fighting drugs in the field of immuno-oncology. The company’s lead candidate, h1B11-12, is a glycoprotein cytokine antibody drug that targets a key protein involved in the generation of suppressive myeloid cells for the treatment of colorectal cancer. It also develops D094 and D099, which are small molecule myeloid targeted prodrug candidates to treat cancer; and myeloid targeting lipid nanoparticles (LNPS) formulations. ME Therapeutic...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2014
• Country: Canada
• Stock Exchange: Canadian Securities Exchange
• Ticker Symbol: METX

Financial Performance

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Jul 1, 2026

Data Sources Report a data error